![](https://investorshub.advfn.com/uicon/65709.png?cb=1541673815)
Thursday, December 18, 2008 9:22:13 AM
Thursday December 18, 9:15 am ET
RALEIGH, NC--(MARKET WIRE)--Dec 18, 2008 -- PharmaCom BioVet, Inc. (Other OTC:PHMB.PK - News) is pleased to announce the company is now beginning the process of locating commercial sites throughout the continental United States to begin the full scale build out of the nation's first branded dedicated Veterinary Oncology Centers.
These centers are going to provide cancer treatment to companion animals using licensed proprietary technologies. PharmaCom BioVet, Inc. expects to garner a significant market share of the overwhelming 41 billion dollar per year veterinary market as the result of early efforts put in by management in seeking out superior treatments and devices.
According to Sharon Berthold, Executive Vice President of PharmaCom BioVet, Inc., "Recent collaborations with world renowned veterinary oncology specialists have allowed us the opportunity to create what I believe are the foremost in companion animal oncology treatments. Recent financial commitments from Investment bankers have allowed us the opportunity to build out our centers on a national scale. We will be concentrating heavily on the branding of PharmaCom BioVet, Inc. using a marketing plan which includes commercials and literature to be distributed to veterinary partners."
About Us:
PharmaCom BioVet, Inc. (PHMB) is quickly positioning itself to become the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized veterinary oncology treatment centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer greater life expectancy and decreased suffering.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.
Contact:
Contact:
Investor Relations
919-572-6395
investors@pharmacombiovet.com
--------------------------------------------------------------------------------
Source: PharmaCom BioVet, Inc.
In case my ihub IRP is out of order: http://www.pinksandbb.com/compensation_disclosure.aspx
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM